# Study of TN-001 Topical Eyedrops for Keratoconus

> **NCT07388069** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **TheiaNova Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Keratoconus

## Interventions

- **DRUG:** Low-dose TGF-B3 and Dexamethasone Sodium Phosphate
- **DRUG:** High-dose TGF-B3 and Dexamethasone Sodium Phosphate

## Key facts

- **NCT ID:** NCT07388069
- **Lead sponsor:** TheiaNova Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388069, "Study of TN-001 Topical Eyedrops for Keratoconus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07388069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*